149 related articles for article (PubMed ID: 11576929)
1. Metabolic consequences of hyperhomocysteinemia in uremia.
Perna AF; Ingrosso D; Satta E; Romano M; Cimmino A; Galletti P; Zappia V; De Santo NG
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S85-90. PubMed ID: 11576929
[TBL] [Abstract][Full Text] [Related]
2. Plasma proteins containing damaged L-isoaspartyl residues are increased in uremia: implications for mechanism.
Perna AF; Castaldo P; De Santo NG; di Carlo E; Cimmino A; Galletti P; Zappia V; Ingrosso D
Kidney Int; 2001 Jun; 59(6):2299-308. PubMed ID: 11380834
[TBL] [Abstract][Full Text] [Related]
3. [Hyperhomocysteinemia in chronic renal failure.].
Satta E; Perna AF; Lombardi C; Acanfora F; Violetti E; Romano MM; Capasso R; Pisano M; Paduano F; De Santo NG
G Ital Nefrol; 2006; 23(5):480-9. PubMed ID: 17123261
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia.
Perna AF; Ingrosso D; De Santo NG; Galletti P; Zappia V
Kidney Int; 1995 Jan; 47(1):247-53. PubMed ID: 7731153
[TBL] [Abstract][Full Text] [Related]
5. Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S-adenosylhomocysteine.
Perna AF; Ingrosso D; Zappia V; Galletti P; Capasso G; De Santo NG
J Clin Invest; 1993 Jun; 91(6):2497-503. PubMed ID: 8514862
[TBL] [Abstract][Full Text] [Related]
6. Toxic effects of hyperhomocysteinemia in chronic renal failure and in uremia: cardiovascular and metabolic consequences.
Perna AF; Capasso R; Acanfora F; Satta E; Lombardi C; Ingrosso D; Violetti E; Romano MM; De Santo NG
Semin Nephrol; 2006 Jan; 26(1):20-3. PubMed ID: 16412820
[TBL] [Abstract][Full Text] [Related]
7. Disturbed homocysteine and methionine cycle intermediates S-adenosylhomocysteine and S-adenosylmethionine are related to degree of renal insufficiency in type 2 diabetes.
Herrmann W; Schorr H; Obeid R; Makowski J; Fowler B; Kuhlmann MK
Clin Chem; 2005 May; 51(5):891-7. PubMed ID: 15774574
[TBL] [Abstract][Full Text] [Related]
8. Hyperhomocysteinemia and macromolecule modifications in uremic patients.
Perna AF; Capasso R; Lombardi C; Acanfora F; Satta E; Ingrosso D
Clin Chem Lab Med; 2005; 43(10):1032-8. PubMed ID: 16197294
[TBL] [Abstract][Full Text] [Related]
9. Epigenetics in hyperhomocysteinemic states. A special focus on uremia.
Ingrosso D; Perna AF
Biochim Biophys Acta; 2009 Sep; 1790(9):892-9. PubMed ID: 19245874
[TBL] [Abstract][Full Text] [Related]
10. Possible mechanisms of homocysteine toxicity.
Perna AF; Ingrosso D; Lombardi C; Acanfora F; Satta E; Cesare CM; Violetti E; Romano MM; De Santo NG
Kidney Int Suppl; 2003 May; (84):S137-40. PubMed ID: 12694330
[TBL] [Abstract][Full Text] [Related]
11. Tissue levels of S-adenosylhomocysteine in the rat kidney: effects of ischemia and homocysteine.
Kloor D; Delabar U; Mühlbauer B; Luippold G; Osswald H
Biochem Pharmacol; 2002 Feb; 63(4):809-15. PubMed ID: 11992651
[TBL] [Abstract][Full Text] [Related]
12. Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations.
Green TJ; Skeaff CM; McMahon JA; Venn BJ; Williams SM; Devlin AM; Innis SM
Br J Nutr; 2010 Jun; 103(11):1629-34. PubMed ID: 20089204
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of altered aspartyl residues in erythrocyte membrane proteins from patients with sporadic amyotrophic lateral sclerosis.
D'Angelo S; Trojsi F; Salvatore A; Daniele L; Raimo M; Galletti P; Monsurrò MR
Neurochem Int; 2013 Nov; 63(6):626-34. PubMed ID: 24044898
[TBL] [Abstract][Full Text] [Related]
14. Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine.
Stam F; van Guldener C; ter Wee PM; Kulik W; Smith DE; Jakobs C; Stehouwer CD; de Meer K
Am J Physiol Renal Physiol; 2004 Aug; 287(2):F215-23. PubMed ID: 15271686
[TBL] [Abstract][Full Text] [Related]
15. Hyperhomocysteinemia is associated with decreased erythropoietin expression in rats.
Grenz A; Hermes M; Hammel P; Roll JB; Osswald H; Kloor D
Cell Physiol Biochem; 2010; 26(3):449-56. PubMed ID: 20798530
[TBL] [Abstract][Full Text] [Related]
16. Hyperhomocysteinemia in uremia--a red flag in a disrupted circuit.
Perna AF; Ingrosso D; Violetti E; Luciano MG; Sepe I; Lanza D; Capasso R; Ascione E; Raiola I; Lombardi C; Stenvinkel P; Massy Z; De Santo NG
Semin Dial; 2009; 22(4):351-6. PubMed ID: 19708980
[TBL] [Abstract][Full Text] [Related]
17. Causes of hyperhomocysteinemia in patients with chronic kidney diseases.
Garibotto G; Sofia A; Valli A; Tarroni A; Di Martino M; Cappelli V; Aloisi F; Procopio V
Semin Nephrol; 2006 Jan; 26(1):3-7. PubMed ID: 16412817
[TBL] [Abstract][Full Text] [Related]
18. Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation.
Cetin O; Bekpinar S; Unlucerci Y; Turkmen A; Bayram C; Ulutin T
Clin Nephrol; 2006 Feb; 65(2):97-102. PubMed ID: 16509458
[TBL] [Abstract][Full Text] [Related]
19. Hyperhomocysteinemia-mediated DNA hypomethylation and its potential epigenetic role in rats.
Jiang Y; Sun T; Xiong J; Cao J; Li G; Wang S
Acta Biochim Biophys Sin (Shanghai); 2007 Sep; 39(9):657-67. PubMed ID: 17805460
[TBL] [Abstract][Full Text] [Related]
20. Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation.
van Guldener C; Stam F; Stehouwer CD
Clin Chem Lab Med; 2005; 43(10):1026-31. PubMed ID: 16197293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
